Else Nutrition (BABY) Q3 2025 earnings summary

Executive summary

• Achieved significant operational turnaround in Q3 2025, marked by gross margin expansion, cost reduction, and disciplined execution for sustainable growth.

• Focused on stabilization, restructuring, and innovation in plant-based nutrition, positioning for long-term value creation and profitability.

• Actively addressing supply chain challenges and preparing for regulatory milestones in plant-based infant formula.

Financial highlights

• Gross margin improved to 34% from negative 9% year-over-year and negative 3.7% (or negative 4%) last quarter.

• Operating expenses reduced by 68% year-over-year to $1.15 million from $3.56 million.

• Monthly cash burn dropped below $200,000, down from $1.15 million a year ago.

• Q3 2025 revenue was $1.66 million, compared to $1.79 million in Q3 2024, impacted by temporary out-of-stock issues.

• Operating loss reduced to $0.58 million from $3.72 million in Q3 2024.

• Cash position at quarter-end was $91K, including restricted cash.

Outlook and guidance

• Expects revenue growth to resume as inventory stabilizes and operational improvements continue.

• Targeting cash flow break-even between late 2026 and early 2027.

• Plans to sustain gross margin improvements through 2026 and beyond.

• Preparing for the next clinical phase to advance plant-based infant formula toward market readiness.

• Priorities include expanding margins, operational efficiency, clinical and regulatory progress, and global partnerships.